Figure 25.1 Schematic representation of the theoretical effect of neuroprotective, symptomatic, or mixed neuroprotective and symptomatic treatments compared with placebo in different study designs. The x-axis represents time and the…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 23 Functional imaging markers as outcome measures in clinical trials for Parkinson’s disease Ryan R. Walsh Introduction There is currently no validated functional imaging marker…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 22 Rating scales and clinical outcome measures in the evaluation of patients with Parkinson’s disease Pablo Martinez-Martin and Carmen Rodríguez-Blázquez Introduction In recent years, the…
Figure 20.1 A sagittal slice through the thalamus taken 14.5 mm from the midline. The ventral intermediate nucleus, shown in red, is the target for tremor therapy in deep-brain stimulation…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 21 Emerging targets and other stimulation-related procedures in the management of Parkinson’s disease Tiago A. Mestre and Elena Moro Introduction Since the first report from…
Figure 18.1 Microelectrode mapping of the globus pallidus. Characteristic firing patterns seen in the striatum (1), globus pallidus externus (GPe) (2), border cells (3) and globus pallidus internus (GPi) (4)….
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 17 Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson’s disease Malco Rossi, Daniel Cerquetti, Jorge Mandolesi and Marcelo Merello Introduction Surgery for movement disorders,…
Figure 15.1 Summary flowchart for the treatment of sleep disorders in Parkinson’s disease resulting from evidence-based data. Levels of recommendation are based on the American Academy of Neurology practice parameters…
Figure 7.1 Levodopa plasma concentrations with standard oral therapy, for a patient taking five daily doses of levodopa/carbidopa perorally (100+100+75+75+100mg every second hour). Graph published with permission from Dag Nyholm….
Figure 14.1 Outline of dopamine replacement therapy. Reprinted with permission, Cleveland Clinic Center for Medical Art and Photography, 2014. All Rights Reserved. Unfamiliarity with the delicate nuances of DRT can…
